{"id":992606,"date":"2026-08-10T07:33:26","date_gmt":"2026-08-10T11:33:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/"},"modified":"2026-08-10T07:33:26","modified_gmt":"2026-08-10T11:33:26","slug":"ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/","title":{"rendered":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY"},"content":{"rendered":"

<\/p>\n

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–The DJS Law Group<\/a> reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (\u201cARS\u201d or \u201cthe Company\u201d) (NASDAQ: SPRY<\/a>) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p>\n

\nShareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

CLASS PERIOD:<\/b> March 9, 2026 to June 24, 2026<\/p>\n

DEADLINE: <\/b>October 5, 2026<\/p>\n

CASE DETAILS: <\/b>According to the Complaint, the Company made false and misleading statements to the market. ARS knew its timeline for CVS Caremark formulary and coverage approval decisions for neffy faced issues. The Company\u2019s commercialization plans would be impacted by this delay. Based on these facts, ARS\u2019s public statements were false and materially misleading throughout the class period.<\/p>\n

\nIf you are a shareholder who suffered a loss, contact us to participate<\/a>.<\/p>\n

WHY DJS LAW GROUP?<\/b> DJS Law Group\u2019s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

Join the case<\/a> to recover your losses.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260810445026\/en\/<\/a><\/span><\/p>\n

\nDavid J. Schwartz
\n
DJS Law Group
\n
274 White Plains Road, Suite 1
\n
Eastchester, NY 10709
\n
Phone: 914-206-9742
\n
Email: David@djslawllp.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (\u201cARS\u201d or \u201cthe Company\u201d) (NASDAQ: SPRY) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2026 to June 24, 2026 DEADLINE: October 5, 2026 CASE DETAILS: According to the Complaint, … <\/p>\n

Continue reading “ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992606","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (\u201cARS\u201d or \u201cthe Company\u201d) (NASDAQ: SPRY) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2026 to June 24, 2026 DEADLINE: October 5, 2026 CASE DETAILS: According to the Complaint, … Continue reading "ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY\",\"datePublished\":\"2026-08-10T11:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/\",\"name\":\"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-10T11:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/","og_locale":"en_US","og_type":"article","og_title":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk","og_description":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (\u201cARS\u201d or \u201cthe Company\u201d) (NASDAQ: SPRY) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2026 to June 24, 2026 DEADLINE: October 5, 2026 CASE DETAILS: According to the Complaint, … Continue reading \"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-10T11:33:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY","datePublished":"2026-08-10T11:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/","name":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-10T11:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260810445026r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-spry-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 SPRY"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992606"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}